Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

Young Kwang Chae¹,²,³,*, Keerthi Ranganath³,*, Peter S. Hammerman⁴, Christos Vaklavas⁵, Nisha Mohindra¹,²,³, Aparna Kalyan¹,²,³, Maria Matsangou¹,²,³, Ricardo Costa¹, Benedito Carneiro¹,²,³, Victoria M. Villaflor¹,²,³, Massimo Cristofanilli¹,²,³ and Francis J. Giles¹,²,³

¹ Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA
² Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
³ Northwestern University Feinberg School of Medicine, Chicago, IL, USA
⁴ Dana Farber Cancer Institute, Boston, MA, USA
⁵ Division of Hematology Oncology, University of Alabama Birmingham, Birmingham, AL, USA

* These authors have contributed equally to this work

Correspondence to: Young Kwang Chae, email: young.chae@northwestern.edu

Keywords: fibroblast growth factor receptor inhibition

Received: September 24, 2016  Accepted: November 22, 2016  Published: December 22, 2016

ABSTRACT

The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase signaling pathway that has a fundamental role in many biologic processes including embryonic development, tissue regeneration, and angiogenesis. Increasing evidence indicates that this pathway plays a critical role in oncogenesis via gene amplification, activating mutations, or translocation in tumors of various histologies. With multiplex sequencing technology, the detection of FGFR aberrations has become more common and is tied to cancer cell proliferation, resistance to anticancer therapies, and neoangiogenesis. Inhibition of FGFR signaling appears promising in preclinical studies, suggesting a pathway of clinical interest in the development of targeted therapy. Phase I trials have demonstrated a manageable toxicity profile. Currently, there are multiple FGF inhibitors under study with many non-selective (multi-kinase) inhibitors demonstrating limited clinical responses. As we progress from the first generation of non-selective drugs to the second generation of selective FGFR inhibitors, it is clear that FGFR aberrations do not behave uniformly across cancer types; thus, a deeper understanding of biomarker strategies is undoubtedly warranted. This review aims to consolidate data from recent clinical trials with a focus on selective FGFR inhibitors. As Phase II clinical trials emerge, concentration on patient selection as it pertains to predicting response to therapy, feasible methods for overcoming toxicity, and the likelihood of combination therapies should be utilized. We will also discuss qualities that may be desirable in future generations of FGFR inhibitors, with the hope that overcoming these current barriers will expedite the availability of this novel class of medications.

INTRODUCTION

The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a receptor tyrosine kinase (RTK) signaling pathway that fundamentally regulates embryogenesis, angiogenesis, tissue homeostasis, and wound repair [1, 2]. It also plays important roles in diverse cell functions, including proliferation, differentiation, apoptosis and migration [3-5]. Many prior studies indicate that alterations in FGFR signaling are associated with a
broad range of congenital craniofacial developmental disorders. Relatively recently, we have come to understand that somatic mutations of FGFR also have a role in oncologic evolution which makes this pathway of interest when exploring the realm of cancer-directed therapy. Tyrosine kinase signaling pathways have been successfully targeted in malignancies, examples include EGFR in non-small cell lung cancer (NSCLC) [6], KIT in gastrointestinal stromal tumors [7], and ERBB2 breast cancers [8], to name a few.

In this review we will assess the current state of clinical trials involving FGFR directed therapy, discuss the limitations of selecting appropriate patient populations, explore likely side effects to these medications along with methods to counteract them, and propose qualities necessary for subsequent generations of FGFR/FGF pathway drugs. We ultimately need to re-evaluate how we can better develop strategies to bring direct FGFR inhibitors into the clinical setting.

**FGF/FGFR SIGNALING PATHWAY**

The FGF family contains 22 known ligands and FGFs interact with the extracellular matrix as well as the cell surface via stabilization by heparan sulphate proteoglycans (HSPGs). The communications of FGFs with HSPGs has been shown to be essential for FGF signal transduction [9]. In comparison, there are only 4 highly conserved transmembrane tyrosine kinase receptors (FGFR1-4) identified in the FGFR family. The members differ from one another in their ligand affinities and tissue distribution with variations in splicing of FGFR1-3 accounting for some additional diversity [10-13]. The fifth related receptor, FGFR5 (also known as FGFR5L1), can bind FGFs but has no tyrosine kinase domain and its role in cellular transduction remains unclear [14, 15]. Though there is no concrete evidence, it is hypothesized that FGFR5L1 may serve as a ligand trap and bind FGFs, may dimerize with other transmembrane FGFRs and inhibit autophosphorylation, or may increase turnover rates of other FGFRs [16].

![Figure 1: Molecular aberrations leading to FGFR pathway activation.](image-url) The FGFRs dimerize upon ligand binding and trigger a downstream cascade of signaling pathways. The FGFR receptors (1-4) can become activated by mutation, translocation, or gene amplification. An increase in circulating FGF ligands can also cause activation. Downstream signaling can trigger the mitogen activated protein kinase (MAPK) pathway, the phosphoinositide-3-kinase (PI3K/Akt) pathway, the phosphorylation of the signal transducer and activator of transcription (STAT), and the PLCγ activation of the DAG-PKC and IP3-Ca²⁺ cascade resulting in DNA transcription. Negative feedback loops can attenuate the signaling cascade at varying levels. As seen above, the “similar expression to FGF” (SEF) family members can interact with the cytoplasmic domain of FGFRs and inhibit downstream signaling. It is hypothesized that FGFR5L1 (atypical receptor/FGFR5) may serve as a ligand trap, may dimerize with other transmembrane FGFRs and inhibit autophosphorylation, or may increase turnover rates of other FGFRs [16]. No evidence exists for these mechanisms.
Upon ligand binding, FGFRs dimerize and trigger a cascade of downstream signaling pathways, including the mitogen activated protein kinase (MAPK), signal transducer and activator of transcription (STAT), the phosphoinositide-3-kinase (PI3K)/Akt pathways, and DAG-PKC and IP3-Ca$^{2+}$ signaling branches via PLCγ activation [17-20]. The FGFR signaling pathway represents a major target for cancer therapeutics as a number of studies indicate that it plays a crucial role in tumor proliferation, angiogenesis, migration, and survival.

**DEREGULATION OF FGFR SIGNALING IN CANCER**

There are several proposed mechanisms for FGFR related oncogenesis including: (i) activating or “driver” mutations resulting in cell growth and survival; (ii) neo-angiogenesis; and (iii) acquired resistance to other cancer therapy [21].

The FGFR pathway is subject to various somatic aberrations resulting in carcinogenesis. Receptor overexpression can be a result of gene amplification or changes in post-transcriptional processing; point mutations may result in constitutive receptor activation or decreased sensitivity to ligand binding; translocations can produce fusion proteins with constitutive activity; and isoform switching and alternative splicing can reduce specificity to FGFs [22]. These major oncogenic aberrations represent features that make FGFR an ideal therapeutic target for treating a broad scope of malignancies.

**FGFR AMPLIFICATION**

Using next generation sequencing (NGS) to detect FGFR anomalies, a comprehensive review of a cohort of nearly 5,000 cancer patients found aberrations in 7.1% of malignancies. FGFR1 amplification was the most common abnormality within the overall scope of FGFR anomalies; notably FGFR4 was also seen to have high rates of amplification [23].

**FGFR1**

Amplification of the chromosomal region 8p11-12, the genomic location of FGFR1, has been detected in 10%
of breast cancers (predominantly in estrogen receptor (ER) positive cancers) and this finding has been related to higher FGFR1 expression levels correlating to worse prognosis [24]. Recently, it has also been reported that FGFR1 is amplified in as many as 19% of squamous non-small cell lung cancers (SqCLC) [25]. Moreover, preclinical studies have shown that a subset of FGFR1-amplified small cell lung cancer is extremely sensitive to FGFR inhibition by PD173074, a specific FGFR1 inhibitor [26]. FGFR1 amplifications have also been reported in oral squamous cell carcinoma [27], ovarian cancer [28], bladder cancer [29] and rhabdomyosarcoma [30].

FGFR3

In a study using microarray-based comparative genomic hybridization on samples from 18 patients with recurrent or metastatic adenoid cystic carcinoma (ACC), the investigators noted that 61% of tumors displayed a DNA copy number increase that was associated with loci for FGFRs. In particular, a gain at the region for FGFR3 was detected more frequently in clinically aggressive tumors [31]. Interestingly, earlier work in ACC had identified FGFR1 overexpression by immunohistochemistry, which was thought to have a role in neoplastic progression as well though this was not seen with the microarray analysis [32]. Interestingly, a phase II clinical trial in 32 patients with ACC demonstrating clinical progression on standard therapy used the pan-FGFR inhibitor dovitinib (NCT01417143) and demonstrated modest anti-tumor activity [33].

FGFR 4

Amplification and activating mutations in FGFR4 have been identified in 7-8% of rhabdomyosarcoma patients and FGFR inhibitors are potentially effective in a rhabdomyosarcoma mouse model expressing mutated FGFR4 [34]. A variety of preclinical studies have shown FGFR4 overexpression with a role in prostate cancers [35], colon cancers [36], and liver cancers [37]. FGFR4 is the only FGFR receptor expressed in mature hepatocytes and in a subset of patients with HCC (~30%), overexpression of both FGF19 and FGFR4 is observed. Among the physiologic functions of the FGF19-FGFR4 axis is a major role in the regulation of hepatic bile acids via a negative feedback system controlling de novo hepatic bile acid synthesis. In patients with extrahepatic cholestasis, plasma levels of FGF19 are elevated which is consistent with our understanding of this pathway. Inhibition of this axis is thus hypothesized to result in a disruption of bile acid homeostasis [38].

**Clinical Landscape for Selective FGFR Inhibitors: Phase Ib/II Trials**

Figure 2: Selected overview of phase II clinical trials evaluating FGFR Inhibitors as monotherapy or in combination with existing therapies. Bladder, Lung, and Gastric cancers all are areas of interest in advanced clinical trials testing FGFR pathway inhibition. There exist a wide scope of histologies where FGFR inhibition may be of clinical benefit, many phase II trials are currently in the recruiting stages or are actively ongoing.
# Table 2: Selected anti-FGFR Drugs in Clinical Phases of Development

| Drug | Histology | Study Phase | Biomarker | Result/ Response | Toxicity | Clinical Trial ID/ Reference |
|------|-----------|-------------|-----------|------------------|----------|-----------------------------|
| **Non-specific** | | | | | | |
| Dovitinib (Novartis) | Urothelial Carcinoma | Phase II | Study Terminated | Thrombocytopenia (9%), fatigue (9%), and asthenia (9%) | NCT00790426 [78] |
| Dovitinib (Novartis) | Urothelial Carcinoma | Phase II – Ongoing, Not Recruiting | FGFR3 by IHC and mutation status | 8% CR (6-month TURBT confirmed, 0% in IHC+, Mut – and 33% in IHC+, Mut +) | Hypertension (15%), hypertriglyceridemia (15%), hepatotoxicity (1%), stomatitis, rash | NCT01732107 [142] |
| AZD4547 (AstraZeneca) | Advanced Solid Tumors | Phase I Complete | FGFR1 amplification by FISH (FGFR1:CEP8≥ 2) | | NCT00979134 |
| SqCLC Expansion Cohort | Ib-Complete | SqCLC: PR in 1/14, SD 4/14 | | | [88] |
| GC and GEJC | Ib - Complete | GC/GEJC: PR in 1/13, SD in 4/13 | | | [89] |
| Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumors | Phase II – Recruitment status unknown | FGFR2 (GC/GEJC) or FGFR1 (BC) gene amplification by FISH | GC/GEJC: RR was 33% (3/9) in FGFR2 amplified tumors BC: RR 12.5% (1/8) FGFR1 amplified tumors | Fatigue (71%), mucositis (41%), nausea (35%), and nail changes (24%). Asymptomatic RPED occurred in 1 pt | NCT01795768 [90] |
| Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced GE or GEJC cancers (SHINE) | Phase II – Completed | FGFR2 status by FISH, and exploratory biomarker analysis. Marked intra-tumor heterogeneity | PFS for FGFR2 amplified arm: AZD4547 1.5M v. 2.3M for Paclitaxel | Stomatitis (20%), dry mouth (17.5%), RPED(15%) | NCT01457846 [143] |
| Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV SqCLC (Arms I/III) | Phase II/III | FGFR1/2/3 mutation, fusion, amplification | | | NCT02154490 |
| BGJ398 (Novartis) | BGJ398 for Patients With Tumors With FGFR Genetic Alterations | Phase II – Active, not recruiting | FGFR genetic alteration | | NCT02160041 |
| BGJ398 (Novartis) | BGJ398 for Patients With Tumors With FGFR Genetic Alterations | Phase I- Recruiting | FISH/CISH | | NCT01004224 |
The same review mentioned above also noted that gene mutations and rearrangements affecting FGF/FGFR signaling were less common than amplification [23].

**FGFR 2**

Mutations in FGFR 2 are implicated in a broad spectrum of malignant disease. Mutations are present in 12% of endometrial carcinomas and FGFR2 mutant endometrial cancer cell lines are highly sensitive to FGFR tyrosine kinase inhibitors, implicating FGFR2 as an innovative therapeutic target in endometrial carcinoma [39]. Also, approximately 10% of cases of gastric cancer are associated with FGFR2 amplification and/or mutation; in particular amplification is suggestive of a poor prognosis and more widespread disease [40]. Gastric cancer cell lines with FGFR2 amplifications show evidence of ligand-independent signaling and are highly sensitive to FGFR inhibitors [41].

**FGFR MUTATION**

The same review mentioned above also noted that gene mutations and rearrangements affecting FGF/FGFR signaling were less common than amplification [23].

| Study Description | Phase | FGFR Mutations | Mutations | Response Rate | Toxicities | Study Number |
|-------------------|-------|----------------|-----------|---------------|------------|--------------|
| FGFR1 amplification | Ib | Urothelial Carcinoma | 12% | 36% | hyperphosphatemia, as well as stomatitis, alopecia, decreased appetite, and fatigue | NCT02657486 |
| FGFR3 activating mutation | Ib | Urothelial Carcinoma | 10% | 42% | hyperphosphatemia (42%), constipation (36%), fatigue (36%), elevated creatinine (36%) | NCT01975701 |
| FGFR3 activating mutation or gene fusion | Pilot Study - Recruiting | Urothelial Carcinoma | 9/25 (36%) | 42% | hyperphosphatemia (50%), fatigue (42%), constipation (38%), cough (23%), and nausea (23%) | NCT02150967 [145] |
| FGFR2 gene fusion/ translocation | Phase II – Active, not recruiting | Urothelial Carcinoma | 3/22 (PR), 15/22 (SD, 10 w/ tumor reduction) | 50% | hyperphosphatemia (50%), fatigue (42%), constipation (38%), cough (23%), and nausea (23%) | NCT02706691 |
| FGFR1/2/3 mutation, amplification, or translocation | Phase IIa – Not yet recruiting | Urothelial Carcinoma | 4/23 CR, 1/23 unconfirmed PR in glioblastoma, urothelial and endometrial cancer. 16/23 with SD | 65% | hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%). | NCT01703481 [97] |
| FGFR2 or FGFR3 translocations | Phase I – Active, not recruiting | Urothelial Carcinoma | 2/20 (CR) | 42% | hyperphosphatemia (42%), constipation (36%), fatigue (36%), elevated creatinine (36%) | NCT01703481 [97] |
| FGFR2 activating mutation | Phase II - Recruiting | Urothelial Carcinoma | 9/25 (36%) | 42% | hyperphosphatemia (42%), constipation (36%), fatigue (36%), elevated creatinine (36%) | NCT01703481 [97] |
| FGFR2 gene fusion/ translocation | Phase II – Recruiting | Urothelial Carcinoma | 3/22 (PR), 15/22 (SD, 10 w/ tumor reduction) | 50% | hyperphosphatemia (50%), fatigue (42%), constipation (38%), cough (23%), and nausea (23%) | NCT02706691 |
| FGFR2 or FGFR3 translocations | Phase I - Recruiting | Urothelial Carcinoma | 4/23 CR, 1/23 unconfirmed PR in glioblastoma, urothelial and endometrial cancer. 16/23 with SD | 65% | hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%). | NCT01703481 [97] |
| FGFR1/2/3 mutation, amplification, or translocation | DNA or RNA based assay | Urothelial Carcinoma | 9/25 (36%) | 42% | hyperphosphatemia (42%), constipation (36%), fatigue (36%), elevated creatinine (36%) | NCT01703481 [97] |
| FGFR1/2/3 mutation, amplification, or translocation | DNA or RNA based assay | Urothelial Carcinoma | 9/25 (36%) | 42% | hyperphosphatemia (42%), constipation (36%), fatigue (36%), elevated creatinine (36%) | NCT01703481 [97] |
| FGFR2 or FGFR3 translocations | DNA or RNA based assay | Urothelial Carcinoma | 4/23 CR, 1/23 unconfirmed PR in glioblastoma, urothelial and endometrial cancer. 16/23 with SD | 65% | hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%). | NCT01703481 [97] |
| FGFR2 or FGFR3 translocations | DNA or RNA based assay | Urothelial Carcinoma | 4/23 CR, 1/23 unconfirmed PR in glioblastoma, urothelial and endometrial cancer. 16/23 with SD | 65% | hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%). | NCT01703481 [97] |

RR = Response Rate; PR = Partial Response; CR = Complete Response; SD = Stable Disease; PFS = Progression free survival; GC = Gastric Cancer; GEJC = Gastroesophageal Junction Cancer; BC = Breast Cancer; SqCLC = Squamous cell lung cancer; *Information up to date as of September 2016
FGFR3 mutations are found in approximately 70% of non-muscle-invasive bladder cancers and 10-20% of invasive bladder cancers [48]. The presence of an FGFR3 mutation strongly relates to low-grade, non-muscle-invasive tumors with a better prognosis, however the clinical viability of FGFR3 as a target for cancer directed therapy in this population is unclear and remains controversial [48]. Interestingly, in patients with non-invasive bladder cancer after resection, the presence of an FGFR3 mutation in cells obtained from urinalysis at routine follow-up was predictive of disease recurrence [49]. FGFR3 mutations have also been identified in many other cancer types, including 3% of squamous cell lung carcinoma [23], cervical cancers [50], multiple myeloma [51], prostate cancer [52] and spermatocytic seminomas [53]. In head and neck squamous cell carcinoma (HNSCC) that was positive for human papilloma virus (HPV, 42.5% of 120 tumor samples), genomic analysis using parallel sequencing technology revealed nearly 18% of tumors with mutations in FGFR2 or FGFR 3, which was notably different than in HPV negative samples [54]. Recent investigation attempted to further elucidate the relevance and prognostic significance of FGFR3 mutation in HNSCC. Interestingly, HPV negative cases that had FGFR3 mutations were not as responsive to FGFR inhibition as the single HPV positive case studied, suggesting further need for study in HNSCC based on HPV status [55]. FGFR3-activating mutations are also found at a high frequency in epidermal nevi and seborrheic keratosis, which are benign skin conditions and do not progress to malignancy [56, 57]. In contrast to the activation of FGFR3 by mutation, amplifications of FGFR3 have been rarely described in cancers.

**FGFR REARRANGEMENTS/FUSION**

Of the 4 FGFR receptors, FGFR2 and FGFR3 are identified as having comparatively more frequent gene rearrangements [23]. In a comprehensive survey of gene fusions across different solid tumor histologies, the authors described a wide-ranging distribution of FGFR1, FGFR2, and FGFR3 fusions across 8 of 20 tumor types analyzed [58].

**FGFR 1**

The 8p11 myeloproliferative syndrome (EMS) demonstrates peripheral blood leukocytosis with eosinophilia, myeloid hyperplasia of the bone marrow, and T-cell lymphoblastic leukemia/lymphoma. Clinically, EMS is overall aggressive with a brief chronic phase prior to rapid transformation into acute leukemia. All cases show a chromosomal abnormality implicating the FGFR1 gene at chromosome 8p11. The novel chimeric activated fusion proteins consist of an N-terminal portion with a dimerization domain and the C-terminal portion that houses the FGFR1 tyrosine kinase domain [59]. Pre-clinical evidence suggests that FGFR inhibitors are able to reduce growth and induce apoptosis in cell lines harboring FGFR1 gene rearrangements [60].

**FGFR 2**

Intrahepatic cholangiocarcinoma demonstrates FGFR2 fusions in 13.6% of cases that are mutually exclusive with KRAS/BRAF mutations, and in vivo cellular studies confirm the oncogenic potential of this aberration. These studies also indicated a potent sensitivity to FGFR inhibitors [61].

**FGFR 3**

It has been shown that nearly 15% to 20% of multiple myeloma cases involve the chromosomal translocation t(4;14), bringing FGFR3 and the adjacent multiple myeloma SET domain (MMSET) gene under the control of the Ig heavy chain promoter. This leads to the aberrant expression of FGFR3 and MMSET [51, 62]. It is important to note that chromosomal translocation t(4;14) myeloma cell lines are highly sensitive to FGFR3 targeting inhibition [62]. Fusion aberrations have been described in FGFR 1-3 genes with multiple partners (examples include TACC1, TACC2, TACC3, BAIAP2L1, NPM1, AFF3) across a wide spectrum of tumor histologies. The TACC3 gene (transforming acidic coiled-coil containing protein) was first identified as a component of FGFR3-TACC3 fusion in glioblastoma multiforme (GBM) and bladder urothelial tumors, this fusion protein is constitutively
active and has been shown to affect mitosis by altering chromosomal segregation patterns [63, 64]. In an analysis of nearly 600 cases of lung adenocarcinoma patients without any smoking history, investigators found an FGFR3-TACC3 fusion in a tissue sample from a patient that previously did not have any known oncogenic alteration. As a whole, tumors harboring FGFR3-TACC3 were identified in 0.5% of the entire cohort (including those cases with known oncogenic mutations such as EGFR).

In vitro, these cells with an FGFR3-TACC3 fusion demonstrated sensitivity to pan-FGFR inhibitors, suggesting a possible subset of lung adenocarcinoma patients that may benefit from targeting this pathway [65].

It is also worth mentioning that we described the first 3 cases of cervical cancer harboring the FGFR-TACC3 fusion, noting that one patient received treatment with FGFR targeted therapy and achieved stable disease for 4 cycles [64, 66].

**AUTOCRINE/PARACRINE SIGNALING**

Most of the genetic aberrations discussed above lead to constitutive receptor activation and ligand-independent signaling. However, ligand-dependent signaling may also occur and would suggest that ectopic expression...
of FGFs can promote cancer. Many preclinical models have done exactly this with the expression of FGF in either cancer cells or stromal cells, showing the autocrine and paracrine stimulation of cancer cells, respectively. Evidence of these autocrine and paracrine circuits have been identified in melanomas [67], in NSCLC [68], prostate adenocarcinomas [69], and in triple negative breast cancers [70]. Increased FGF release from stromal or tumor cells may have a role in cell survival, proliferation, and angiogenesis.

ANTI-FGF/FGFR THERAPEUTIC APPROACHES

In an effort to capitalize on FGF/FGFR signaling in tumorigenesis, a number of novel drugs targeting the FGF/FGFR cascades have been introduced and are currently undergoing preclinical and clinical trials in various FGFR-related tumors. Early development of FGFR inhibitors exhibits antitumor activity and present very specific toxicity profiles. Prior studies also indicate that FGFR inhibitors enhance tumor sensitivity to conventional anticancer drugs such as 5-fluorouracil, irinotecan, paclitaxel, and etoposide in human cancer cells acquiring anti-apoptotic potential based on aberrant FGFR activation [71, 72].

Current FGFR inhibitors can be divided into groups according to the mechanism of action: (i) small molecules, which are commonly classified as receptor tyrosine kinase inhibitors (TKIs). TKIs are mainly ATP-competitive molecules binding to the cytoplasmic kinase domain and either inhibit the catalytic activity of FGFRs or the autophosphorylation of tyrosine residues; (ii) antagonistic antibody or peptide inhibitors, which bind to the FGFR extracellular domain and compete with FGFs, thereby blocking FGF-FGFR association and FGFR dimerization; (iii) FGF ligand traps, which can potentially block the activity of multiple FGF ligands and receptors, exerting both anti-angiogenic and anti-proliferative effects.

Within the group of small molecule inhibitors, there exist both nonselective and selective FGFR TKIs. Nonselective FGFR TKIs are compounds that bind to the relatively conserved ATP-binding domain in RTKs and as their name implies, lack kinase selectivity. The nonselective FGFR TKIs target other RTKs such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs), and usually present modest bioactivity against the FGFR family. Most of the RTKs assessed to date are non-selective FGFR inhibitors. Dual inhibition with VEGFRs/PDGFRs has the obvious potential benefit of simultaneously targeting angiogenesis and tumor cell proliferation. However, many of these TKIs with multiple targets are less potent against the FGFR signaling pathway and give rise to a variety of toxic side effects in clinical and preclinical studies, thereby limiting the ability to deliver drugs at doses required for FGFR inhibition [73, 74]. Pan-FGFR inhibitors such as lenvatinib (E7080), ponatinib (AP24534), regorafenib (BAY 73-4506), dovitinib (TKI258), lucitanib (E3810), cediranib (AZD2171), intedanib (BIBF 1120), brivanib (BMS-540215), and others are currently being studied in clinical trials. These agents fall into the spectrum of multi-kinase TKI’s which have FGFR as a part of their portfolio of inhibition.

NON-SELECTIVE FGFR INHIBITORS

Dovitinib (TKI258, Novartis) is an example of a well-studied second-generation non-selective FGFR inhibitor targeting FGFRs and other RTKs. It inhibits both the kinase activity of FGFR1, FGFR2, and FGFR3 in FGFR-amplified breast cancer and the cellular activity of FGFR3 in t(4;14) multiple myeloma in pre-clinical studies [75, 76]. Dovitinib shows high potency against most FGFRs in addition to targeting c-KIT, CSF-1, VEGFRs and PDGFRs. Antitumor activity in advanced renal cell carcinoma via inhibition of FGFR1 has been demonstrated in Phase I and II clinical trials [77, 78]. A Phase III trial comparing dovitinib against sorafenib for metastatic renal cell carcinoma in the third line setting included 570 patients and dovitinib was not shown to be superior to sorafenib with respect to progression free survival (PFS) or overall survival (OS) [79]. Interestingly, despite the high potency against FGFRs, one Phase II trial in advanced urothelial carcinoma using dovitinib to treat FGFR3 mutated versus FGFR wild-type cancer failed to show a meaningful overall response rate and the study was terminated after concluding that dovitinib has limited single-agent activity in this population [80]. Additional Phase II trials in urothelial bladder cancer are ongoing (NCT01732107). TKI258 recently underwent a series of clinical trials for its safety and efficacy in patients with breast cancer (NCT00958971), endometrial cancer (NCT01379534), and multiple myeloma (NCT01058434).

Lenvatinib (E7080, Eisai) is another multikinase inhibitor, inhibiting FGFR1-4 as well as VEGFR1-3, RET, KIT and PDGFR-β [81]. In vivo, lenvatinib shows more potent anti-tumor activity than it does in vitro. In a triple negative human breast adenocarcinoma xenograft model, lenvatinib demonstrated significant growth inhibition of primary mammary fat pad tumors, intra-tumoral angiogenesis, lymphangiogenesis, and development of lung and lymph node metastasis [82]. Lenvatinib inhibits FGFR1 with an IC_{50} of 46 nmol/L, which is highly potent at a clinically relevant concentration [81].

A Phase 1 dose-escalation study of lenvatinib in subjects with advanced solid tumors and an expanded cohort of patients with melanoma enrolled 77 subjects and determined a maximum tolerated dose (MTD) of 10mg by mouth twice daily (BID) [83]. The notable toxicities included hypertension (43%), fatigue (42%),
and proteinuria (39%), all of whom have been identified in other VEGF inhibitors. GI side effects included nausea (25%). Twelve patients (15.6%) achieved partial response (PR, n = 9) or unconfirmed PR (uPR, n = 3), and 19 (24.7%) achieved stable disease (SD) ≥23 weeks. The most encouraging tumor response in this cohort was in melanoma, however a promising response was also seen in medullary thyroid cancer.

The FDA approved lenvatinib in 2015 for use in radio-iodine refractory, well-differentiated thyroid carcinoma. Recent data from a Phase I trial studying lenvatinib in combination with carboplatin/paclitaxel in treatment naïve advanced NSCLC, demonstrated a MTD of 4mg by mouth BID, with manageable side effects and encouraging anti-tumor activity [84]. In a cohort of 28 patients, a 68% response rate was noted with a median PFS of 9 months. Biomarkers that correlated with disease response were stromal cell-derived factor 1 alpha, stem cell factor, and granulocyte colony-stimulating factor.

Ongoing Phase II/III clinical trials include a comparison of lenvatinib with sorafenib in hepatocellular carcinoma (NCT01761266), lenvatinib with everolimus in renal cell carcinoma (NCT02454478), and as monotherapy in unresectable biliary cancer (NCT02579616).

A further understanding of the predictive significance of various biomarkers is needed, and screening for FGFR in advanced cancer across tumor histologies may play a role in selecting patients likely to have the best response to therapy. We have evidence that lenvatinib has anti-tumor activity across multiple malignant histologies. This should prompt further study, as is not certain if the observed benefit stems mainly from FGFR inhibition or from suppression of many other pathways altogether.

**SELECTIVE FGFR INHIBITORS**

Subsequent pharmaceutical development has led to highly selective and highly bioactive FGFR inhibitors (i.e., selective FGFR TKIs). These include compounds like AZD4547, BGJ398, JNJ42756493, and PD173074.

**AZD4547**

AZD4547 is a small-molecule compound that is a selective FGFR (FGFR 1-3) inhibitor, delivered orally in capsule form. The drug demonstrated potent inhibition of proliferation in cell lines with activation of the FGFR pathway and also in tumor xenograft models [85]. Oral administration of AZD4547 has also resulted in prolonged survival of FGFR3-TACC3-transformed glioma xenografts by 28 days compared with mice treated with the vehicle control [63]. Furthermore, inhibition with AZD4547 resulted in a significant dose-dependent tumor growth inhibition and survival of gastric cancer carrying an FGFR2 gene amplification both in vitro and in vivo [86]. Other pre-clinical studies on xenograft models transplanted with transformed cells derived from FGFR1 amplified NSCLC cancer patients have shown that AZD4547 stops tumor growth and promotes regression [87].

A Phase I, open label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD4547 in patients with advanced solid malignancies was completed in March 2015 (NCT00979134). A dose escalation study (80 patients) identified 80mg PO BID as the recommended dose. The increase in serum phosphate concentration observed in this phase I study provides evidence that AZD4547 at this dose leads to pharmacologic target inhibition. Dose limiting toxicities reported were elevated liver enzymes, mucositis, stomatitis, renal failure, and hyperphosphatemia. Expansion cohorts to further assess safety and tolerability required tumors with FGFR 1 amplification as confirmed through FISH (FGFR: Centromeric ratio ≥ 2). In a cohort of 15 patients with FGFR1 amplified SqCLC, the most common adverse events (AEs) were dermatologic and GI related. Grade ≥ 3 adverse events (AEs) occurred in 3 patients (central serous retinopathy (CSR), dehydration, hyponatremia). Treatment related severe AEs occurred in 3 patients as well (CSR, asthenia and dyspnea). There were no deaths due to the drug but 3 discontinuations due to AEs [88].

In a cohort of 13 gastroesophageal cancer patients, the reported AEs included vomiting in 8 patients, decreased appetite and diarrhea in 7 patients, fatigue and nausea in 6 patients, hyperphosphatemia, constipation and dry eyes (4 patients each), stomatitis in 5 patients, and retinal pigment epithelial detachment in 4 patients [89].

Of note, partial response (PR, by RECIST criteria) was observed in tumors with a high burden of FGFR aberration including one SqCLC patient with FGFR1 amplification and another patient with FGFR2 amplified gastroesophageal cancer. 4 patients in each cohort were also noted to have stable disease [88, 89].

AZD4547 is currently under a Phase II clinical trial to assess its activity in patients with FGFR1 or FGFR2 amplified breast, squamous lung, and stomach cancer whose cancers have progressed following previous chemotherapy (NCT01795768). 285 patients with advanced cancer were screened, identifying FGFR1 amplification in 18% (20/111) HER2 negative breast cancer, 9.5% (4/42) NSCLC, and FGFR2 amplification in 7.6% (10/132) gastroesophageal (GC). Confirmed RR was 33% (3/9) in FGFR2 amplified GC, and 12.5% (1/8) FGFR1 amplified BC. Similar AEs were reported. These preliminary results indicate that AZD4547 demonstrated high activity in FGFR2 amplified GC and lower activity in FGFR1 amplified BC. The investigators noted that FGFR2 copy number in cell free plasma DNA was elevated in all PR of GCs; this may provide a screening tool to
identify FGFR2 amplified GC with likelihood of treatment response [90].

AZD4547 is also being evaluated both against existing therapies and in conjunction with existing therapies in a variety of Phase II trials. A recently completed Phase II trial aimed to evaluate the safety and efficacy of AZD4547 versus paclitaxel in advanced gastric or gastro-oesophageal junction cancer; no results have been reported (NCT01457846). AZD4547 is also undergoing a Phase I/II clinical trial in combination with fulvestrant versus fulvestrant alone in ER+ breast cancer patients with FGFR1 amplification (NCT01202591).

BGJ398

BGJ398 (Novartis) is an additional potent, pan-FGFR inhibitor currently undergoing Phase I/II clinical trials after initially demonstrating antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3 [91]. A dose escalation trial is actively ongoing (NCT01004224) and preliminarily has reported a maximum tolerated dose of 125mg/day with a 21-day on/7-day off schedule for dosing based on safety data. Of the 94 enrolled patients initially, partial responses were seen in 4 FGFR3 mutated bladder cancers, 2 FGFR1 amplified SqCLC, and a reduction in tumor burden was seen in FGFR2 fusion cholangiocarcinoma as well as in FGFR1 amplified breast cancer [92]. Investigators used FISH to screen for FGFR1 amplification, and in the cohort of 17 SqCLC (expansion arm) patients there were 4/17 PRs (2 after data cutoff date) and 3 patients with SD. Major adverse effects were reversible hyperphosphatemia, as well as stomatitis, alopecia, decreased appetite, and fatigue [93]. These study results suggest efficacy, and as such, efforts to optimize predictive biomarkers for FGFR inhibitor sensitivity are ongoing. Recently multiple investigators have suggested that high levels of FGFR1 mRNA are more indicative of response to TKIs in pre-clinical models of SCC and a subset of head and neck squamous cell cancers (specifically to BGJ398 in HNSCC) [94, 95]. Trials that are actively recruiting for study of BGJ398 alone exist for non-muscle invasive urothelial squamous cell cancers (specifically to BGJ398 in HNSCC) [94, 95]. Trials that are actively recruiting for study of BGJ398 alone exist for non-muscle invasive urothelial carcinoma (NCT02657486), recurrent glioblastoma (NCT01975701), and advanced cholangiocarcinoma (NCT02150967). Additionally, pre-clinical data suggests that gastrointestinal stromal tumors (GIST) demonstrating resistance to imatinib may be secondary to FGF pathway activation [96]; a Phase I/II clinical trial is actively recruiting to evaluate BGJ398 in combination with imatinib in untreated advanced GIST (NCT02257541).

JNJ-42756493

JNJ-42756493 (Janssen) is another pan-FGFR inhibitor that is orally bioavailable. Initial data from a Phase I trial to evaluate the safety, pharmacokinetics, and pharmacodynamics in adult patients with advanced or refractory solid tumors or lymphoma recommends a 10mg (7 days-on/7 days-off schedule) as the appropriate tolerable dose with clinical response (NCT01703481). Biomarkers in this study included tumor tissue genomic profiling, skin/tumor biopsies and soluble serum markers. Of the 65 patients enrolled, 23 were evaluated for response to treatment and investigators identified 5/23 patients that responded (4 confirmed, and 1 unconfirmed partial response). Stable disease (SD) was seen in 16/23 patients with glioblastoma, urothelial or endometrial cancer. All patients that responded demonstrated FGFR2 or FGFR3 translocations, and of the responses identified, 3 of the patients with partial responses harbored an FGFR3-TACC3 fusion alteration. Similar to other selective FGFR inhibitors, the most common adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%). Dose-dependent elevations in serum phosphate were seen to represent pharmacodynamic effect of the medication [97]. A Phase II trial in urothelial cancer and a Phase I trial in advanced hepatocellular carcinoma are actively recruiting (NCT02365597, NCT02421185).

MONOCLONAL ANTIBODIES

In addition to RTKIs, several monoclonal antibodies targeting FGF/FGFR are in preclinical or early phase development; these are directed toward a particular FGFR and interfere with ligand binding or receptor dimerization. The goal is to reduce the potential toxicity of pan-FGFR inhibition given the specificity of antibody-antigen interactions.

An FGFR2-IIIb-specific antibody, GP369, has been shown to inhibit the proliferation of human cancer cell lines and tumor xenografts with amplified or activated FGFR2 signaling [98]. BAY1187982 (Bayer) also falls under the spectrum of exploiting the antibody/antigen relationship as a human anti-FGFR2-Ab that is conjugated to a cytotoxic agent (antibody-drug conjugate). Proof of efficacy has been seen in pre-clinical studies demonstrating successful monotherapy for inhibiting tumor growth in gastric and breast cancer xenograft models that demonstrate FGFR2 overexpression [99]. A phase I dose-escalation trial in patients with advanced stage solid tumors known to express FGFR2 had initially set out to establish a MTD in two cohorts, those with triple negative breast cancer and a second group to encompass other tumors expressing FGFR2 (NCT02368951). Unfortunately, for unknown reasons, the trial was recently terminated.

Antibodies targeting FGFR3 have also been shown to have significant inhibitory effect on cell proliferation in bladder cancer cells [100] and t (4; 14)-positive multiple
myeloma [101]. MFGFR1877S (Genentech) is a human anti-FGFR3 monoclonal antibody that demonstrated activity in preclinical models of urothelial carcinoma harboring FGFR3 overexpression. Subsequently there have been two Phase I trials completed, one in solid tumors (NCT01363024) and one in t(4; 14)-positive multiple myeloma (NCT01122875). Preliminarily results from the solid tumor trial reported 4/10 with SD in urothelial carcinoma. The DLT was noted to be thrombocytopenia in a single patient. A recommended Phase 2 dose (RP2D) was determined, however further plans for study and development remain unknown at this time [102].

**FGF-LIGAND TRAPS**

The third approach to targeting the FGF/FGFR signaling pathway is to impede ligand binding to the receptor itself by developing FGF-ligand traps. FP-1039 (GSK3052230, GlaxoSmithKline) is a soluble fusion protein that consists of extracellular FGFR1-IIIc fused to the Fc domain of IgG1 and hampers binding of FGF1, FGF2, and FGF4 (AACR 2014 Abstract #5449). A phase II trial in patients with endometrial cancer (NCT01244438) was suspended due to lack of viability given that after screening 70 patients, none qualified for the study. A subsequent Phase II trial is currently recruiting and is looking to evaluate FP-1039 in solid tumors alone, or in combination with docetaxel, paclitaxel and carboplatin (NCT01868022).

**EXPANDING FGFR DIRECTED THERAPIES: FROM THEORY TO PRACTICE**

Given the broad scope of malignancies with FGF/FGFR pathway aberrations, proof of concept has been demonstrated for its role as a driver for oncogenesis, as a downstream key player in angiogenesis, and as a pathway responsible for acquired resistance to other anti-cancer therapies. Pre-clinical and clinical studies have shown that cancers harboring FGF/FGFR pathway aberrations are likely to be sensitive to FGFR inhibitors across various histologies. Ongoing Phase I/II clinical trials have demonstrated reduction in disease burden or stable disease, with evidence of dose dependent increase in serum phosphate, FGF23, and Vitamin D levels indicating likely markers to follow if effectively targeting the FGF/FGFR pathway [103].

Although non-selective FGFR inhibitors are approved for various indications, there are currently no selective FGFR inhibitors that are FDA approved. Ongoing clinical trials highlight the barriers to reaching this goal - how to select the right patient population to better achieve clinical disease response, how to predict and bypass mechanisms of acquired resistance, managing the toxicity profile, and utility in combination with existing anti-cancer therapy.

**BIOMARKER DEVELOPMENT FOR PATIENTS WITH TUMORS HARBORING FGF/FGFR PATHWAY ABERRATIONS**

As aforementioned, a recent study used next generation sequencing (NGS) to characterize frequencies of FGFR aberrations in nearly 5,000 solid tumor samples [23]. They found that 7.1% of malignancies demonstrated detectable abnormalities with the most common being gene amplification, followed by mutations, then rearrangements. FGFR1, as previously discussed, was most commonly affected. Within the cohort of malignancies analyzed, urothelial carcinoma exhibited the highest percentage of FGFR aberrancy (largely mutation, then amplification, followed by fusion) at 32%. Breast cancer, endometrial cancer, squamous lung cancers, and ovarian cancer followed in order of decreasing frequency [23]. Notably there was no evaluation of FGF ligand dependent signaling, highlighting that a subset of patients with FGF/FGFR pathway aberrations may still benefit from FGFR targeted therapy but were not characterized in this study. In their previous work, this group had noted FGF anomalies in approximately 14% of all malignancies [104]. Ultimately, when evaluating all FGF/FGFR aberrations (mutations, amplifications, rearrangements, etc.) they are detectable in nearly 20% of cancer histologies when assessed in combination [104].

Much of the pre-clinical and early clinical data come from trials in patient populations unselected for FGF/FGFR pathway abnormalities. The true response rates or clinical benefits for those whose cancers harbor FGF/FGFR abnormalities may be higher than observed in unselected patient populations. Many ongoing Phase I/II trials can be commended for aiming to select patients with specific FGF/FGFR alterations, and at this stage (appropriately so) there exist a variety in the methods including FISH, chromogenic in situ hybridization (CISH), quantitative real-time PCR, and NGS. Preliminary data, as discussed above, indicate tumor response with FGFR targeted therapies. However, detecting an aberration alone does not necessarily appear to predict tumor response. With FISH and IHC there is heterogeneity in expression of FGF/FGFR aberrations that may very well depend on the segment of tissue obtained at biopsy.

We must additionally consider that FGF/FGFR pathway alterations likely vary in their role depending on tumor histology and interactions with other oncogenic pathways. For example, one can learn from the development of EGFR inhibitors and the predictive biomarkers for response and resistance in both colon cancer and advanced squamous cell head and neck cancer. Recall that cetuximab was first approved for colorectal cancer with EGFR expression by IHC in 2004.
It was later found out that EGFR expression by IHC in colorectal cancer did not correlate with response to therapy, and subsequent investigation led to the identification of the KRAS mutation conferring resistance [106]. Further study revealed that the best responders were also wild-type for both KRAS and NRAS [107]. This information is now included in the NCCN guidelines on the treatment of metastatic colorectal cancer prior to treatment with targeted EGFR therapy. Interestingly there is no specific methodology recommended (ie. sequencing or hybridization) in testing for these mutations [108]. In contrast, in advanced squamous cell head and neck cancers, testing for KRAS, NRAS, or EGFR expression did not correlate with a predicted response to EGFR targeted therapy. Cetuximab is currently approved in the metastatic setting for palliation as well as with concurrent radiation for definitive treatment of this malignancy without biomarker testing as a pre-requisite [109, 110]. This suggests that though a single pathway inhibitor works in two different histologies, the biomarkers for response or resistance may be different. The same may hold true for FGFR inhibitors.

As further studies unfold, we need to utilize multiplex molecular testing such as NGS to screen tumors harboring specific molecular aberrations of interest and increase the likelihood of detecting actionable FGFR alterations in each patient. Granted, even this technique may be limited by the location of biopsy and tumor heterogeneity especially in the setting of metastatic disease. While still a developing technology, a further biomarker analysis might include a measure of serum or urine circulating tumor DNA (ctDNA) in order to overcome this barrier. There are some studies that have identified a high concordance for actionable mutations between paired plasma and tumor specimens, especially for metastatic disease in non-small cell lung cancer, breast cancer, and colorectal cancer [111]. In the ongoing clinical trial NCT01795768 (a proof of concept Phase II Trial for AZD4547) as discussed above, the authors identified that all of the FGFR2 amplified gastric cancers that responded to therapy had elevated levels of circulating cell free plasma DNA [90]. There is a continued interest in urine ctDNA as well, as a completely non-invasive method of monitoring tumor dynamics in response to therapy. A recent study assessed the burden of ctDNA KRAS in a cohort of 13 patients with metastatic colorectal carcinoma (6 KRAS WT, 7 KRAS G12/13 mutants by tissue biopsy) using a commercial method for urine based ctDNA monitoring (PCR followed by NGS) which demonstrated stronger concordance with the clinical course and had fewer temporal fluctuations when compared to the dynamics of ctDNA KRAS in blood. In 1 patient, the urinary ctDNA increase even preceded radiographic disease progression by 2 months [112].

The accessibility of testing would likely allow for frequent monitoring of tumor evolution, and the presence of novel molecular alterations while actively receiving anti-cancer treatment may predict upcoming resistance to therapy. Already this has been described in a small cohort of patients with colorectal cancer initially demonstrating KRAS wild-type tumors, which subsequently were noted to have molecular alterations (via serum analysis) including KRAS, NRAS, EGFR, and BRAF after treatment with anti-EGFR therapies [113]. With a very sensitive testing approach you can pick up a resistant clone and theoretically modify your treatment regimen prior to disease progression. There still remain many questions with this technique, we first and foremost need to see that using ctDNA analysis to guide therapy leads to improved outcomes compared to molecular analysis from tumor biopsies. Whether this approach is relevant for FGFR targeted therapies remains to be seen with a validated translational study. Ideally, we could use this approach to monitor treatment response, disease recurrence, as well as pick up resistant clones in patients that have an FGFR alteration being treated with an FGFR inhibitor.

New trial designs and approaches are being developed in order to capture the many malignancies that may harbor an FGF/FGFR aberration. The Lung-MAP trial (umbrella trial) has been designed to study 4 targeted agents and 1 immunotherapy drug in patients with advanced stage IIIIB/IV SquCLC with AZD4547 being one of the study drugs in target therapy group. It is a phase II/III, open label, multi-center study to assess the progression free survival and is still ongoing [114]. The inclusion is presence of FGFR 1/2/3 alterations, which are determined by FoundationOne test (NCT02154490). Phase II navigation clinical trials such as the BGJ398 basket trial for all solid tumors and hematologic malignancies and the NCI-MATCH are currently in development and will provide us with insight and direction as to better biomarker selection for response and resistance. The NCI-MATCH Trial (opened August 2015, NCT02465060) is designed as true histology agnostic basket trial for all solid tumors, with a plan to enroll rare cancers to account for at least 25% of the participants. The trial was paused several months after it opened due to rapid enrollment, and has since re-opened as of May 2016 with a plan to incorporate more sub arms (up to 24 total) which will include an FGFR inhibitor arm (AZD4547) [115].

RESISTANCE MECHANISMS AND THE FGFR PATHWAY

Thus far we have discussed the use of FGFR inhibitors assuming that FGF/FGFR is the primary driver for oncogenesis in certain histologies or in certain molecular aberrations such as FGFR3 fusion in bladder cancer [116]. However, it is clear that the downstream signaling pathways in the FGF/FGFR cascade are highly interrelated, suggesting that FGF/FGFR inhibition should also be considered as a means to overcome acquired...
resistance to therapy in other malignancies. Additionally, we must appreciate the evolving nature of cancer cells and the likelihood of resistance to FGFR inhibitors directly either by (i) compensatory signaling or (ii) via intrinsic gatekeeper mutations in the FGFR receptors themselves.

**FGF/FGFR inhibitors as a means to overcome acquired resistance to various cancer treatments**

Recently, acquired resistance to EGFR specific inhibitors in NSCLC mutant cell lines has been hypothesized to relate to the activation of the FGFR1-FGF2 autocrine loop [117]. FGFR is also involved in autocrine activation of STAT3 as a positive feedback in many previously treated cancer cells that are driven by oncogenes such as EGFR, ALK, MET, and KRAS [118].

In KRAS-mutant lung adenocarcinoma, in particular, strategies to inhibit the KRAS protein directly have not produced consistent results [119]. As such, the focus has shifted to targeting key downstream RAS pathway proteins including mitogen-activated protein kinase enzyme MEK (a component of the MAPK pathway), with one such drug being trametinib (MEK inhibitor). *In vitro* studies established that KRAS-mutant lung tumor cell lines treated with trametinib demonstrated an increase in FGFR1 receptor and/or ligand expression. This subsequently led to increased signaling through alternate pathways like AKT and ERK, which ultimately resulted in adaptive drug resistance [119]. Combining trametinib with ponatinib (multi-kinase inhibitor including pan-FGFR inhibition) resulted in a synergistic effect that allowed for continued inhibition of cell proliferation. This effect was appreciated in cell lines and xenograft mouse models of KRAS-mutant lung adenocarcinoma and KRAS-mutant pancreatic carcinoma, but was not as significant in KRAS wild-type lung cancer cells or KRAS mutant colon cancer. The effect was sustained with the use of AZD4547 and BG1398 suggesting that it is inhibition of FGFR that likely accounts for the synergistic effect and not the inhibition of other RTK pathways. Interestingly, ponatinib alone had minimal effect on KRAS-mutant cells. The investigators made several conclusions, first that the compensatory response involving FGFR1 appears specific to particular KRAS-mutant cancer histologies. Secondly, they hypothesize that a combination of MEK and FGFR inhibition would likely be a valid approach in the treatment of KRAS-mutant lung cancer [119].

Much work has also been done investigating the relationship of FGF/FGFR with VEGF; preclinical models have shown that exposure to anti-VEGF treatment results in higher expression of FGF2 as the cancer progressed. Subsequent FGF blockade impaired further cancer growth [120]. This has been observed in both colorectal cancer and glioblastoma patients after exposure and failure to respond to anti-angiogenic/VEFG directed therapies [121].

In colorectal cancer cell lines demonstrating resistance to oxaliplatin or 5-fluorouracil (5-FU), a synergistic interaction between BGJ398 (silencing FGFR4) and these therapies was demonstrated to lead to reduction in cell growth and survival [122]. In breast cancer, FGFR1 amplification has been associated with endocrine resistance and poor prognosis [123]. These observations have led to the design of clinical trials evaluating malignancies that have failed standard therapies, with the idea that resistance *via* tyrosine kinase pathways may be a contributing factor in failure to respond. The interactions of the FGFR pathway and other known carcinogenic pathways suggest the role of FGFR signaling in acquired cancer therapy resistance by promoting cell survival and limiting overall drug response.

**Primary resistance mechanisms to FGF/FGFR pathway inhibitors**

In the development of a novel targeted therapy, we must also recognize the inevitability of acquiring resistance to the drug - either from up-regulation of compensatory pathways or innate mutations rendering the FGFR receptor resistant.

In a study using FGFR3-mutant cell lines, the investigators identified EGFR signaling as a key mechanism in limiting FGFR3 inhibition. In partially dependent FGFR3 cell lines, inhibiting FGFR3 resulted in a temporary down regulation of MAPK signaling that was bypassed by a prompt up regulation in EGFR signaling [124]. In EGFR dependant cell lines, they also identified that EGFR downstream signaling dominated, even in the presence of an activating FGFR3 mutation.

More recently, in SqCLC cell lines with FGFR1 amplification, investigators identified clonal cell populations that were resistant to treatment with AZD4547 or BAY1163877. They subsequently discovered the overexpression and activation of MET in these cell lines, and interestingly in cells treated with AZD4547 they identified MET gene amplification. In these AZD4547 treated cells, MET amplification was thought to lead to resistance through ErbB3 activation. The concurrent inhibition of MET signaling with the aforementioned FGFR inhibitors resulted in a reduction in cell growth. Additionally, when the investigators forced ectopic expression of MET in the SqCLC cells, they found that this conferred resistance to targeted FGFR inhibition. Overall, it appears that concurrent inhibition of MET and FGFR signaling pathways may provide synergistic benefit [125].

In discussing innate mutations, the “gatekeeper” mutation is responsible for the most common type of kinase inhibitor resistance, these are mutations of a residue located in the ATP binding pocket of the RTK. Learning from our prior experiences may allow for
anticipatory guidance in the FGF/FGFR tale. Take for example the treatment of chronic myelogenous leukemia (CML). Since the approval of imatinib in 2001 targeting the constitutively active tyrosine kinase BCR-ABL, we have seen the development of second and third generation tyrosine kinase inhibitors (TKIs) as increasing identification of resistance and intolerance unfolded [126]. A recent framework has been proposed to aid the clinician in selecting the appropriate TKI in their treatment of CML [127]. Imatinib, and both second-generation drugs, dasatinib and nilotinib, are currently FDA approved as first-line options for newly diagnosed CML in the chronic phase (CML-CP). For patients who fail this frontline therapy, subsequent salvage therapy options include an alternative second-generation drug (the aforementioned, or bosutinib) or third generation ponatinib. These next generation TKIs are more potent and selective; thus far disease response patterns have been identified as relating to stage of disease, concurrent comorbidities, and BCR-ABL1 mutational status. Of critical importance has been the understanding that patients who develop the T315I “gatekeeper” mutation exhibit resistance to all the available TKIs except ponatinib.

A similar pattern of drug development and understanding has unfolded in the targeted treatment of EGFR mutant NSCLC or ALK-rearranged NSCLC. In treating EGFR mutant NSCLC, the first generation EGFR tyrosine kinase inhibitors gefinitib and erlotinib (approved in 2003 and 2004 respectively), followed by the second-generation afatinib, have been widely used in treatment of advanced disease [128]. However, disease progression frequently occurs after a median of 9 to 13 months of therapy, suggesting acquired resistance to treatment [128]. In fact, the most common acquired EGFR mutation leading to decreased survival has been found to be the “gatekeeper” mutation T790M [129], with nearly 50-60% of resistant cases demonstrating this anomaly [130]. Of course, there exist many other mechanisms for acquired resistance to therapy, including bypass signaling/compensatory activation of alternative RTKs, and downstream signaling molecules to name a few [131]. Continued development of EGFR inhibitor therapy led to the accelerated approval of the third generation EGFR inhibitor osimertinib for patients with metastatic EGFR T790M mutation-positive NSCLC that have progressed on or after previous EGFR inhibitor therapy [132]. Additional third generation agents continue to be in varying stages of clinical development.

In likewise fashion, there has also been significant progress in understanding and treating ALK-rearranged advanced NSCLC [133]. Nearly 5% of advanced NSCLC contain an ALK-rearrangement, for which crizotinib (multitargeted TKI of ALK, ROS1, and MET) was approved in 2010. As observed in the aforementioned stories, resistance to ALK blockade also emerges in time by multiple mechanisms including: ALK kinase mutations (30%) at L1196M (gatekeeper), F1174L, and G1202R, as well as activation of alternate oncogenes with resulting bypass signaling [133]. Second-generation ALK TKIs demonstrate more potent activity against ALK and ALK kinase mutants, and accelerated approval has allowed for ceritinib (2014) and alectinib (2015) to reach patients that have progressed on or are intolerant to crizotinib [134]. With ceritinib, there already exists some emerging data that ALK-G1202R and F1174V/C mutations confer some resistance to therapy [133]. As expected, ongoing study is evaluating newer second and third generation agents. Clearly, recognizing gatekeeper mutations is of clinical relevance in understanding resistance and realizing new actionable targets when designing and selecting the next line of therapy.

As highlighted in the above instances, an analogous pattern is being recognized in the family of FGFR receptors. Several pre-clinical studies have highlighted a significant gatekeeper mutation (FGFR1 V561M, FGFR2 V564I, FGFR3 V555M, FGFR4 V550M) that renders targeted therapy ineffective [135]. Preclinical cellular models harboring the FGFR3 V555M mutation have demonstrated resistance to AZD4547 [136]. Recently, the FGFR1 V561M gatekeeper mutation was characterized at a structural and kinetic level where a 38-fold increase in autophosphorylation of the receptor was demonstrated. Interestingly, the mutated receptor still maintained affinity for AZD4547 [137]. Subsequent generations of FGFR inhibitors will need to be able to circumvent these cellular defense mechanisms, and there exist two compounds FIIN-2 and FIIN-3 developed in preclinical studies that have demonstrated potency against wild type FGFR1-4 as well as receptors with gatekeeper mutations [135]. FIIN-3 in particular appears to have a more pronounced ability to inhibit both FGFR and EGFR signaling and was seen as more potent than FIIN-2 and BGJ398. This is of interest because aside from gatekeeper mutations, there is also evidence that FGFR inhibitor resistance can come from a switch to ERBB2/3 signaling (structurally related to EGFR) in models of FGFR3-dependent cancer cell lines [138]. When designing clinical trials, we should exclude tumors with the aforementioned gatekeeper mutations of FGFR known to confer possible resistance to currently available selective FGFR inhibitors.

COMBINING FGF/FGFR PATHWAY INHIBITION WITH OTHER EXISTING CANCER THERAPIES

Based on the evidence, promising permutations for combined therapy may include FGFR inhibitors with endocrine therapy in breast cancer [123, 139], leading to trials such as AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients who have progressed on non-steroidal aromatase inhibitors. This is a Phase I/II trial that is actively recruiting (NCT01791985).
It’s likely that FGFR inhibitors would also be of clinical benefit in combination with EGFR targeted therapy, anti-VEGF therapy, and MET or MEK inhibitors given the known crosstalk among these oncogenic signaling pathways and the ability for cells to initiate compensatory signaling escape mechanisms when any one pathway is inhibited as previously discussed.

Interestingly, we know that many of the non-specific FGFR inhibitors such as lenvatinib and dovitinib are currently being used as treatment options in the clinical setting. This speaks to the notion that suppression of FGFR signaling in conjunction with other pathways is a valid approach; this may be part of the reason that singularly targeting the FGFR pathway has not resulted in meaningful outcomes warranting FDA approval at this stage.

SAFETY AND TOXICITY OF FGF/FGFR PATHWAY INHIBITION

All the nonselective compounds currently being evaluated have shown toxicities related to VEGFR inhibition and deregulated angiogenesis, such as hypertension, cardiovascular events, and proteinuria. Moreover, the other most commonly reported adverse events include toxicities shared with other targeted agents, including gastrointestinal disorders (vomiting, diarrhea, decreased appetite) and skin reactions (stomatitis), and ocular effects (dry eye, retinal pigment epithelium detachment). Conversely, selective FGFR inhibitors show an “FGFR-specific” toxicity profile, including hyperphosphatemia thought to be related to FGF23 signaling [140]. At present, this has been managed with a low phosphate diet, phosphate binders, and diuretic therapy but there exist no strict guidelines on managing this side effect. A recent review suggested a framework for managing FGFR therapy hyperphosphatemia by first implementing dietary reduction in phosphate, followed by phosphate binders, and then manipulation in dosing schedule as needed. It was recommend that repeated episodes of phosphate ≥ 9mg/dL or simultaneous renal impairment would warrant discontinuation of therapy [140]. Preclinical models as aforementioned have proposed that increases in FGF23 and phosphate level may serve as markers for monitoring therapy, as an “on-target effect”. Ongoing clinical trials will likely continue to provide information regarding treatment monitoring, consider also the possibility of intensively checking calcium and magnesium. An additional point of interest is that a low phosphate diet would likely exclude foods such as chocolate, cheese, and ice cream, which realistically may not align with quality of life goals in patients presenting with advanced malignancies. A possibility exists that a preference not to comply with these dietary recommendations may preclude treatment with FGFR inhibitors altogether.

As is obvious in the field, the long-term consequences of continued FGFR suppression remain to be seen. Many have suggested that other drugs targeting downstream kinases, such as MAPK or PI3K/AKT, could offset intermittent FGFR inhibitor dosing. In the interim, methods for managing side effects will likely continue to emerge.

CONCLUSIONS

The FGF/FGFR pathway demonstrates yet another mechanism that is critically involved in oncogenesis, thereby providing an actionable target for inhibition and exploitation of cell signaling. This comes with the promise to further the era of precision medicine. The traditional approach of tissue biopsy and FISH or IHC to identify mutation status may be inferior given the likelihood of tumor heterogeneity in advanced metastatic disease and also inherent technical limitations with this technique. Already in other known targetable mutations discussed above, such as EGFR in colorectal cancer or BCR-ABL1 in CML, the use of next generation sequencing (NGS) has proved invaluable in identifying not only actionable mutations, but also for screening “gatekeeper” mutations that may confer resistance to therapy. As selective FGFR inhibitors get closer to routine clinical use, we can learn from the past especially with regards to patient selection as it predicts response to therapy. As a whole, the advent of next generation sequencing with the concurrent use of ctDNA (blood or urine) have allowed us to better understand the biology of disease response and resistance in the development of FGF/FGFR inhibitors.

The Lung-MAP trial open through the NCTN (national clinical trials network) includes AZD4547 as one of the drugs in the target therapy group; it remains to be seen if FGFR amplification itself is a strong predictive marker of response to therapy in metastatic SqCLC. The investigators that designed the trial adopted NGS copy number variation to screen patients, however depending on the biomarkers, immunohistochemical assays may also be performed. The use of massive parallel DNA sequencing technology allows for noting differences in disease response based on FGFR mutation or fusion in lung, which may be important in a minority of lung cancers and this detail would be easily missed with FISH or IHC [114]. The NCI-MATCH trial (histology agnostic basket trial for all solid tumors) as aforementioned will also be including an FGFR inhibitor arm with AZD4547. This is an ideal platform to discover unusual responders to FGFR inhibitor therapy with the goal of identifying new and relevant FGF/FGFR alterations, especially with the addition of rare tumors that might otherwise not have enrolled in a clinical trial.

Despite the advances in drug design to include the
second-generation selective FGFR inhibitors, the biology of FGF/FGFR signaling is complex and we have seen that response to therapy is dependent on a multitude of factors. At the present time, targeting FGFR fusion aberrations has demonstrated the best response; we see this in bladder cancer with encouraging results. Two phase I clinical trials (NCT01703481, NCT01004224) using the pan-FGFR inhibitors JNJ-42756493 and BGJ398 respectively, have reported partial response to therapy with FGFR3-TACC3 translocation or FGFR3 activating mutations primarily detected by FISH and IHC [141]. This is of interest given that the tumors in which FGFR3-TACC3 mutations have been identified (2.6% of urothelial carcinoma cases, 1.2-8.3% of GBM) are on the more aggressive end of the spectrum with overall limited treatment options [64]. Ultimately, we have the understanding that the FGF/FGFR aberrations do not behave uniformly across cancer histologies, suggesting both the ongoing need for understanding these differences as well as identifying the optimal strategy for detecting actionable mutations across a broad range of cancer types.

CONFLICTS OF INTEREST

No relevant conflicts of interests to report.

REFERENCES

1. Neilson KM and Friesel R. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J Biol Chem. 1996; 271(40):25049-25057.
2. Keegan K, Johnson DE, Williams LT and Hayman MJ. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A. 1991; 88(4):1095-1099.
3. Becker D, Lee PL, Rodeck U and Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene. 1992; 7(11):2303-2313.
4. Funato N, Moriyama K, Shimokawa H and Kuroda T. Basic fibroblast growth factor induces apoptosis in myofibroblastic cells isolated from rat palatal mucosa. Biochem Biophys Res Commun. 1997; 240(1):21-26.
5. Li M and Bernard O. FDC-P1 myeloid cells engineered to express fibroblast growth factor receptor 1 proliferate and differentiate in the presence of fibroblast growth factor and heparin. Proc Natl Acad Sci U S A. 1992; 89(8):3315-3319.
6. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-2139.
7. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol. 2011; 38 Suppl 1:S10-19.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-792.
9. Harmer NJ, Ilag LL, Mulloy B, Pellegrini L, Robinson CV and Blundell TL. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. J Mol Biol. 2004; 339(4):821-834.
10. Dieci MV, Arnedos M, Andre F and Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013; 3(3):264-279.
11. Thompson LM, Plummer S, Schalling M, Altherr MR, Gusella JF, Housman DE and Wasmuth JJ. A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics. 1991; 11(4):1133-1142.
12. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE and Williams LT. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol. 1992; 12(1):82-88.
13. Avivi A, Skorecki K, Yayon A and Givol D. Promoter region of the murine fibroblast growth factor receptor 2 (bek/KGFR) gene. Oncogene. 1992; 7(10):1957-1962.
14. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD and Murison JG. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001; 271(2):171-182.
15. Wiedemann M and Trueb B. Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. Genomics. 2000; 69(2):275-279.
16. Trueb B. Biology of FGFR1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci. 2011; 68(6):951-964.
17. Chen Y, Li X, Eswarakumar VP, Seger R and Lonai P. Fibroblast growth factor (FGF) signaling through PI3-kinase and Akt/PKB is required for embryoid body differentiation. Oncogene. 2000; 19(33):3750-3756.
18. Doherty P and Walsh FS. CAM-FGF Receptor Interactions: A Model for Axonal Growth. Mol Cell Neurosci. 1996; 8(2/3):99-111.
19. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA and Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000; 19(29):3309-3320.
20. LaVallee TM, Prudovsky IA, McMahon GA, Hu X and Maciag T. Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration. J Cell Biol. 1998; 141(7):1647-1658.
21. Touat M, Ileana E, Postel-Vinay S, Andre F and Soria JC.
Targeting FGFR Signaling in Cancer. Clin Cancer Res. 2015; 21(12):2684-2694.

22. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrete AJ, Nuciforo P and Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014; 25(3):552-563.

23. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J and Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2015.

24. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C and Theillet C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997; 57(19):4360-4367.

25. Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wohrer A, Hackl M, von Deimling A, Streule B and Birner P. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer. 2014; 83(1):83-89.

26. Pardo OE, Latigo J, Jeffery RE, Nye P, Poulsom R, Spencer-Dene B, Lemoine NR, Stamp GW, Aboagye EO and Seckl MJ. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 2009; 69(22):8645-8651.

27. Freier K, Schween C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, Radlwimmer B, Hackl M, von Deimling A, Streule B and Birner P. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer. 2014; 83(1):83-89.

28. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C and Theillet C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997; 57(19):4360-4367.

29. Simon R, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2007; 67(20):9290-9299.

30. Missiaglia E, et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer. 2009; 48(6):455-457.

31. Vekony H, Ylstra B, Wilting SM, Meijer GA, van de Wiel MA, Leemans CR, van der Waal I and Bloemena E. DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res. 2007; 13(11):3133-3139.

32. Myoken Y, Myoken Y, Okamoto T, Sato JD, Kan M, McKeehan WL, Nakahara M and Takada K. Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours. J Pathol. 1996; 178(4):429-436.

33. Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH and Bang YJ. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015; 121(15):2612-2617.

34. Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS and Khan J. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013; 8(10):e76551.

35. Wang J, Stockton DW and Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004; 10(18 Pt 1):6169-6178.

36. Bange J, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Res. 2002; 62(3):840-847.

37. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J, Carano R, D’Souza A, Qing J, Mohtashemi I, Ashkenazi A and French DM. Targeting FGFR1 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008; 27(1):85-97.

38. Mellor HR. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma: translational safety considerations. Liver international : official journal of the International Association for the Study of the Liver. 2014; 34(6):e1-9.

39. Dutt A, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008; 105(25):8713-8717.

40. Jung EJ, Jung EJ, Min SY, Kim MA and Kim WH. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol. 2012; 43(10):1559-1566.

41. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N and Nishio K. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor 2. Cancer Res. 2007; 67(20):9290-9299.

42. Hunter DJ, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007; 39(7):870-877.

43. Turner N and Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-129.

44. Tchaicha JH, Akbay EA, Altabef A, Mikse OR, Kikuchi E, Rhee K, Liao RG, Bronson RT, Sholl LM, Meyerson M, Hammerman PS and Wong KK. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014; 74(17):4676-4684.

45. Tanizaki J, et al. Identification of Oncogenic and Drug-
Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Res. 2015; 75(15):3139-3146.

46. Gartside MG, et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res. 2009; 7(1):41-54.

47. Mak G, Arkenau HT and Chin M. Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment. Melanoma Res. 2014; 24(4):408-412.

48. Liu X, Zhang W, Geng D, He J, Zhao Y and Yu L. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet Mol Res. 2014; 13(1):1109-1120.

49. Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C, Tubach F, Mentre F, Cussenot O and Grandchamp B. The diagnostic and prognostic performance of urinary FGFR3 mutation analysis in bladder cancer surveillance: a prospective multicenter study. Urology. 2015.

50. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23(1):18-20.

51. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM and Bergsagel PL. Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997; 16(3):260-264.

52. Hernandez S, de Muga S, Agell L, Juanpere N, Esgueva R, Lorente JA, Mojal S, Serrano S and Lloreta J. FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol. 2009; 22(6):848-856.

53. Goriel A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, Pfeifer SP, McVean GA, Rajpert-De Meyts E and Wilkie AO. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet. 2009; 41(11):1247-1252.

54. Seiwert TY, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015; 21(3):632-641.

55. von Massenhausen A, et al. Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Target Oncol. 2016.

56. Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstädter F, Zwarthoff EC and Hartmann A. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006; 116(8):2201-2207.

57. Logie A, Dunois-Larde C, Rosly C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP and Radvanyi F. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005; 14(9):1153-1160.

58. Stransky N, Cerami E, Schalm S, Kim JL and Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014; 5:4846.

59. Jackson CC, Medeiros LJ and Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010; 41(4):461-476.

60. Chase A, Grand FH and Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007; 110(10):3729-3734.

61. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge T and Shibata T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59(4):1427-1434.

62. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, Chumakov I, Singer Y, Chang H, Liang SB and Yayon A. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006; 107(10):4039-4046.

63. Singh D, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012; 337(6099):1231-1235.

64. Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK and Giles FJ. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016; 7:55924-38. doi: 10.18632/oncotarget.10482.

65. Capelletti M, et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014; 20(24):6551-6558.

66. Carneiro BA, Elvin JA, Kamath SD, Ali SM, Paintal AS, Restrepo A, Berry E, Giles FJ and Johnson ML. FGFR3-TACC3: A novel gene fusion in cervical cancer. Gynecol Oncol Rep. 2015; 13:53-56.

67. Wang Y and Becker D. Antisense targeting of basic fibroblast growth factor-2 mutations in melanoma. Mol Cancer Res. 2009; 7(1):41-54.

68. Terai H, et al. Activation of the FGFR2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013; 11(7):759-767.

69. Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A and Shibata T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59(4):1427-1434.

70. Wang Y and Becker D. Antisense targeting of basic fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997; 3(8):887-893.

71. Terai H, et al. Activation of the FGFR2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013; 11(7):759-767.

72. Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A and Shibata T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59(4):1427-1434.
growth-factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008; 14(17):5459-5465.
83. Hong DS, et al. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015; 21(21):4801-4810.
84. Nishio M, et al. Phase I study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 2013; 109(3):538-544.
85. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN and Klimowska T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012; 72(8):2045-2056.
86. Xie L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013; 19(9):2572-2583.
87. Zhang J, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived xenograft models. Clin Cancer Res. 2012; 18(24):6658-6667.
88. Paik PK SR, Ferry D, Soria J-C, Mathewson A, Kilgour E, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. 2014 ASCO Annual Meeting J Clin Oncol 32:5s, 2014 (suppl; abstr 8035).
89. Hendrik-Tobias Arkenau MS, Antoine Hollebecque, Alastair Mathewson, Charlotte Rose Lemech, Donal Landers, et al. A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. 2014 ASCO Annual Meeting.
90. Smyth EC, et al. (2015). Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. 2015 ASCO Annual Meeting
91. Guagnano V, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-[(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl]-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011; 54(20):7066-7083.
92. Sequist LV, et al. Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Clin Cancer Res; 2014; 74(19 Supplement):CT326.
93. Nogova L SL, Cassier PA, Hidalgo M, Delord J-P, Schulter MH, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. 2014 ASCO Annual Meeting J Clin Oncol 32:5s, 2014 (suppl; abstr 8034).
94. Göke F, et al. FGFR1 Expression Levels Predict BGJ398
Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res. 2015; 21(19):4356-4364.

95. Wynes MW, et al. FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clin Cancer Res. 2014; 20(12):3299-3309.

96. Pietras K, Pahler J, Bergers G and Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008; 5(1):e19.

97. Tabernerio J, et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2015; 33(30):3401-3408.

98. Bai A, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010; 70(19):7630-7639.

99. Sommer A, et al. Preclinical anti-tumor efficacy of FGFR2-ADC BAY 1187982 in patient-derived gastric, breast and ovarian cancer models. 106th Annual AACR Meeting (Philadelphia, PA). Cancer Res 2015;75(15 Suppl):Abstract nr 1684.

100. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A and Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res. 2005; 11(17):6280-6290.

101. Qing J, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009; 119(5):1216-1229.

102. O’Donnell P GJ, Gordon MS, Shih K, Choi UJ, Lu D, et al. A phase I dose-escalation study of MFGFR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with advanced solid tumors. Eur J Cancer 2012; 48 Suppl 6:191-2.

103. Bahleda R DR, Adamo B, Gazzah A, Infante JR, Zhong B, et al. (2014). Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. ASCO 2014 Annual Meeting J Clin Oncol 32:5s, 2014 (suppl; abstr 2501).

104. Helsten T, Schwaeederle M and Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biological and clinical implications. Cancer Metastasis Rev. 2015; 34(3):479-496.

105. (2004). Drug Approval Package: Erbitux BLA 125084. In: FDA, ed. http://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084.ERBITUX_PRTLBL.PDF.

106. Li XX, Liang L, Huang LY and Cai SJ. Standard chemotherapy with cetuximab for treatment of colorectal cancer. World J Gastroenterol. 2015; 21(22):7022-7035.

107. Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA and Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015; 7(5):252-262.

108. NCCN. (2014). Clinical Practice Guidelines in Oncology: Colon Cancer (Version 2.2015).

109. Alorabi M, Shonka NA and Ganti AK. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role? Crit Rev Oncol Hematol. 2015.

110. Licitra L, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011; 22(5):1078-1087.

111. Ignatiadis M, Lee M and Jeffrey SS. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res. 2015; 21(21):4786-4800.

112. Barzi A, Melnikova V, Vibat CRT, Hancock S, Ning Y, Agafitei D, Erlander MG and Lenz H-J. Abstract B4: Use of urinary circulating tumor DNA (ctDNA) KRAS for monitoring treatment response in patients with metastatic colorectal cancer (mCRC). Mol Cancer Ther. 2015; 14(12 Supplement 2):B4.

113. Diaz LA, Jr., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-540.

114. Ferrarotto R, Redman MW, Gandara DR, Herbst RS and Papadimitrakopoulou VA. Lung-MAP—framework, overview, and design principles. Chinese clinical oncology. 2015; 4(3):36.

115. NCI-MATCH Trial Draws Strong Interest. Cancer Discov. 2016; 6(4):334.

116. Wang QY, Zhao Y and Zhang R. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer. Minerva Med. 2015.

117. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC and Heasley LE. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGFR2-FGFR1 autocrine growth loop. Oncogenesis. 2013; 2:e39.

118. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and Settleman Papadimitrakopoulou VA. Lung-MAP—framework, overview, and design principles. Chinese clinical oncology. 2015; 4(3):36.

119. Manchado E, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016; 534(7609):647-651.

120. Casanovas O, Hicklin DJ, Bergers G and Hanahan D. Drug Approval Package: Erbitux BLA 125084. In: FDA, ed. http://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084.ERBITUX_PRTLBL.PDF.

121. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and Settleman. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014; 26(2):207-221.

122. Manchado E, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016; 534(7609):647-651.

123. Casanovas O, Hicklin DJ, Bergers G and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309.
121. Lieu C, Heymach J, Overman M, Tran H and Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011; 17(19):6130-6139.

122. Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S and Johnston PG. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014; 5:e1046.

123. Turner N, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010; 70(5):2085-2094.

124. Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A and Turner NC. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013; 3(9):1058-1071.

125. Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016; 5(7):e241.

126. Jabbour E, Kantarjian H and Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015; 15(6):323-334.

127. Jabbour E and Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016; 91(2):252-265.

128. Wang S, Cang S and Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016; 9:34.

129. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3):e73.

130. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-2247.

131. Redmond KL, Papafili A, Lawler M and Van Schaeybroeck S. Overcoming Resistance to Targeted Therapies in Cancer. Semin Oncol. 2015; 42(6):896-908.

132. (2015). Drug Approval Package: Tagrisso (osimertinib) tablet, for oral use In: FDA, ed. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf: FDA.

133. Shea M, Costa DB and Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016; 10(2):113-129.

134. (2015). Alectinib. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf: FDA.

135. Tan L, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A. 2014; 111(45):E4869-4877.

136. Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavrie PR and Cook SJ. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2013; 32(25):3059-3070.

137. Sohl CD, Ryan MR, Luo B, Frey KM and Anderson KS. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles’ heel of targeted therapy. ACS Chem Biol. 2015; 10(5):1319-1329.

138. Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK and Hammerman PS. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015; 34(17):2167-2177.

139. Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA and Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol Cancer Ther. 2012; 11(10):2301-2305.

140. Hierro C, Rodon J and Tabernero J. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin Oncol. 2015; 42(6):801-819.

141. Rouanne M, Loriot Y, Lebret T and Soria J-C. Novel therapeutic targets in advanced urothelial carcinoma. Crit Rev Oncol Hematol. 2016; 98:106-115.

142. Hahn NM, et al. Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157. 2015 ASCO Annual Meeting (Chicago, IL). J Clin Oncol 34, 2016 (suppl; abstr 4526).

143. Yung-Jue Bang EVC, Wasat Mansoor, Russell D. Petty, Yee Chao, David Cunningham, David Ferry, Donal Landers, Paul Stockman, Neil R. Smith, Catherine Geh, Elaine Kilgour; . A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. 2015 ASCO Annual Meeting (Chicago, IL). J Clin Oncol 34, 2016 (suppl; abstr 4014).

144. Pal SK, et al. Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations. 2016 ASCO Annual Meeting (Chicago, IL). J Clin Oncol 34, 2016 (suppl; abstr 4014).
145. Milind M. Javle ea. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol 34, 2016 (suppl 4S; abstr 335). 2016.

146. Arlene O. Siefker-Radtke BM, Karel Decaestecker, John M. Burke, Anne O’Hagan, Anjali Narayan Avadhani, Bob Zhong, Ademi E. Santiago-Walker, Peter De Porre, Sabine Brookman-May, Jesús García-Donas. (2016). A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations. 2016 ASCO Annual Meeting. (Chicago, IL). J Clin Oncol 34, 2016 (suppl; abstr TPS4575).

147. Hyman DM, et al. (2016). Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. 2016 ASCO Annual Meeting. (Chicago, IL). J Clin Oncol 34, 2016 (suppl; abstr 2500).